Akari Therapeutics, Plc (AKTX) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth No data.
13/40
1.6 / 5 stars
All 40 Win/Lose results and 80 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 3 losses, 8 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/1 |
WinAKTX / S&P 98.93% / 15.20% |
No dataAKTX / S&P / 15.00% |
No dataAKTX / S&P / 50.40% |
| 2026-Q10/1 |
LoseAKTX / S&P -55.45% / -4.33% |
No dataAKTX / S&P / 11.30% |
No dataAKTX / S&P / 27.70% |
| 2025-Q40/1 |
LoseAKTX / S&P -71.39% / 2.65% |
No dataAKTX / S&P / 9.00% |
No dataAKTX / S&P / 13.40% |
| 2025-Q30/1 |
LoseAKTX / S&P -13.68% / 8.12% |
No dataAKTX / S&P / 4.61% |
No dataAKTX / S&P / 13.45% |
| 2025-Q20/1 |
LoseAKTX / S&P -5.65% / 10.94% |
No dataAKTX / S&P / 4.83% |
No dataAKTX / S&P / 10.63% |
| 2025-Q11/1 |
WinAKTX / S&P 1.64% / -4.27% |
No dataAKTX / S&P / 4.98% |
No dataAKTX / S&P / 10.57% |
| 2024-Q40/1 |
LoseAKTX / S&P -58.64% / 2.41% |
No dataAKTX / S&P / 5.25% |
No dataAKTX / S&P / 6.15% |
| 2024-Q31/1 |
WinAKTX / S&P 9.26% / 5.89% |
No dataAKTX / S&P / 5.89% |
No dataAKTX / S&P / 6.11% |
| 2024-Q21/1 |
WinAKTX / S&P 44.77% / 4.28% |
No dataAKTX / S&P / 5.38% |
No dataAKTX / S&P / 5.12% |
| 2024-Q10/1 |
LoseAKTX / S&P -40.22% / 10.56% |
No dataAKTX / S&P / 5.71% |
No dataAKTX / S&P / 5.59% |
| 2023-Q40/1 |
LoseAKTX / S&P -21.01% / 11.69% |
No dataAKTX / S&P / 6.81% |
No dataAKTX / S&P / 7.78% |
| 2023-Q31/1 |
WinAKTX / S&P 16.18% / -3.27% |
No dataAKTX / S&P / 7.52% |
No dataAKTX / S&P / -5.03% |
| 2023-Q20/1 |
LoseAKTX / S&P -6.59% / 8.74% |
No dataAKTX / S&P / 9.50% |
No dataAKTX / S&P / -8.57% |
| 2023-Q10/1 |
LoseAKTX / S&P -61.28% / 7.50% |
No dataAKTX / S&P / 10.77% |
No dataAKTX / S&P / -15.69% |
| 2022-Q40/1 |
LoseAKTX / S&P -25.40% / 7.56% |
No dataAKTX / S&P / 11.88% |
No dataAKTX / S&P / -17.99% |
| 2022-Q30/1 |
LoseAKTX / S&P -37.00% / -4.88% |
No dataAKTX / S&P / 13.47% |
No dataAKTX / S&P / -1.41% |
| 2022-Q20/1 |
LoseAKTX / S&P -16.67% / -16.10% |
No dataAKTX / S&P / 13.71% |
No dataAKTX / S&P / 11.04% |
| 2022-Q10/1 |
LoseAKTX / S&P -20.00% / -4.60% |
No dataAKTX / S&P / 15.97% |
No dataAKTX / S&P / 42.23% |
| 2021-Q40/1 |
LoseAKTX / S&P -7.98% / 11.03% |
No dataAKTX / S&P / 15.00% |
No dataAKTX / S&P / 96.40% |
| 2021-Q30/1 |
LoseAKTX / S&P -5.78% / 0.58% |
No dataAKTX / S&P / 10.77% |
No dataAKTX / S&P / 69.42% |
| 2021-Q20/1 |
LoseAKTX / S&P -34.47% / 8.55% |
No dataAKTX / S&P / 6.58% |
No dataAKTX / S&P / 51.81% |
| 2021-Q11/1 |
WinAKTX / S&P 42.70% / 6.17% |
No dataAKTX / S&P / -1.06% |
No dataAKTX / S&P / 7.39% |
| 2020-Q40/1 |
LoseAKTX / S&P 6.32% / 12.15% |
No dataAKTX / S&P / -3.72% |
No dataAKTX / S&P / -33.42% |
| 2020-Q30/1 |
LoseAKTX / S&P -20.18% / 8.93% |
No dataAKTX / S&P / -2.04% |
No dataAKTX / S&P / -27.10% |
| 2020-Q21/1 |
WinAKTX / S&P 50.34% / 20.54% |
No dataAKTX / S&P / -0.46% |
No dataAKTX / S&P / -27.11% |
| 2020-Q11/1 |
WinAKTX / S&P -17.14% / -19.60% |
No dataAKTX / S&P / 3.47% |
No dataAKTX / S&P / -14.75% |
| 2019-Q40/1 |
LoseAKTX / S&P 2.34% / 9.07% |
No dataAKTX / S&P / 5.36% |
No dataAKTX / S&P / 2.99% |
| 2019-Q30/1 |
LoseAKTX / S&P -15.35% / 1.70% |
No dataAKTX / S&P / 5.02% |
No dataAKTX / S&P / 0.21% |
| 2019-Q20/1 |
LoseAKTX / S&P -43.58% / 4.30% |
No dataAKTX / S&P / 6.64% |
No dataAKTX / S&P / 8.65% |
| 2019-Q11/1 |
WinAKTX / S&P 128.03% / 13.65% |
No dataAKTX / S&P / 8.12% |
No dataAKTX / S&P / 14.29% |
| 2018-Q40/1 |
LoseAKTX / S&P -38.67% / -13.52% |
No dataAKTX / S&P / 9.05% |
No dataAKTX / S&P / 18.23% |
| 2018-Q31/1 |
WinAKTX / S&P 31.28% / 7.71% |
No dataAKTX / S&P / 10.21% |
No dataAKTX / S&P / 19.06% |
| 2018-Q21/1 |
WinAKTX / S&P 7.14% / 3.43% |
No dataAKTX / S&P / 9.03% |
No dataAKTX / S&P / 14.46% |
| 2018-Q10/1 |
LoseAKTX / S&P -57.97% / -0.76% |
No dataAKTX / S&P / 7.68% |
No dataAKTX / S&P / 12.46% |
| 2017-Q40/1 |
LoseAKTX / S&P -29.48% / 6.64% |
No dataAKTX / S&P / 7.03% |
No dataAKTX / S&P / 13.82% |
| 2017-Q31/1 |
WinAKTX / S&P 33.19% / 4.48% |
No dataAKTX / S&P / 5.68% |
No dataAKTX / S&P / 17.57% |
| 2017-Q20/1 |
LoseAKTX / S&P -58.36% / 3.09% |
No dataAKTX / S&P / 4.83% |
No dataAKTX / S&P / 17.74% |
| 2017-Q11/1 |
WinAKTX / S&P 57.24% / 6.07% |
No dataAKTX / S&P / 3.67% |
No dataAKTX / S&P / 13.32% |
| 2016-Q40/1 |
LoseAKTX / S&P -17.27% / 3.82% |
No dataAKTX / S&P / 2.09% |
No dataAKTX / S&P / 7.05% |
| 2016-Q30/1 |
LoseAKTX / S&P -36.92% / 3.85% |
No dataAKTX / S&P / 0.20% |
No dataAKTX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AKTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.36% | 20.78% |
| Annualized return | -70.36% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AKTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.40% | 83.14% |
| Annualized return | -64.03% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AKTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.88% | 319.30% |
| Annualized return | -48.91% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |